source
- Eli Lilly cuts German weight-loss syringe investment by half amid new cost-cutting lawEli Lilly said it will cut its planned investment in Germany for the production of weight‑loss syringes. The company had originally earmarked $2.67 billion, but will now invest roughly half that a…
- Parabilis Medicines targets over $400 million in Nasdaq IPO to fund peptide pipelineParabilis Medicines, a peptide-focused biotech led by former Johnson & Johnson R&D head Mathai Mammen, announced plans for a Nasdaq initial public offering. The company aims to raise more than $40…